A Breakthrough in Rapid-Acting Psychedelics
A new wave of clinical research is reshaping how we think about treating depression. Recent phase 2 trial results for BPL-003, a 5-MeO-DMT nasal spray, and mebufotenin benzoate spray point to a powerful possibility: psychedelic sprays that deliver meaningful relief from treatment-resistant depression within 24 hours, with effects that can last up to eight weeks (Barron’s / FT).
While these fast-acting psychedelic sprays may soon reach clinics, their true potential lies not just in how quickly they work—but in how well we help seekers turn breakthroughs into sustainable growth.
Why a Psychedelic Spray Works Faster
Conventional antidepressants can take weeks to build up in the body—time that many struggling patients can’t afford. In contrast, psychedelic sprays like BPL-003 work by delivering the active compound directly through the nasal passage, producing rapid absorption and near-immediate effects.
In multi-country trials with nearly 200 patients, participants experienced significant reductions in depression symptoms within hours. Many were stable and ready for discharge within 90 minutes, opening new doors for safe, outpatient treatment and broader accessibility.
Why Integration Still Matters Most
Quick relief is life-changing—but without integration, it’s often temporary.
A psychedelic spray can create a sudden, profound shift in perspective. But daily stress, old patterns, and unresolved trauma can erode those gains if they’re not supported.
At JourneyŌM, we believe integration is where real transformation happens. Our experienced Guides provide a scaffold for lasting change, helping seekers make sense of insights and carry them forward.
Integration support may include:
- Guided breathwork to anchor calm states
- Reflective journaling to track breakthroughs and patterns
- Structured check-ins to navigate challenges and growth
- Personalized coaching to translate insights into daily habits
“JourneyŌM gave me hope when nothing else worked. Their integration support made all the difference—it turned my session into a life shift.”
— Hannah, Seeker
Building Integration-First Care
As psychedelic sprays move toward wider approval, we must ensure integration remains central—not an optional extra.
Clinics and providers should:
- ✅ Bundle Aftercare with Dosing: Every session with a psychedelic spray should come with a clear plan for follow-up and integration.
- ✅ Train & Certify Guides: Practitioners need training in somatic practices, narrative coaching, and trauma-informed care.
- ✅ Secure Coverage: Payers and regulators should treat integration as part of core treatment—unlocking insurance reimbursement and expanding access.
What’s Next for Psychedelic Sprays
Phase 3 trials for BPL-003 and mebufotenin sprays are underway. While researchers refine dosing and confirm safety, some pilot programs are already combining these fast-acting treatments with integration protocols like JourneyŌM’s Journey Pathway.
Future models may also pair human Guides with digital tools: check-in reminders, community forums, and at-home practices to keep seekers supported between sessions.
The JourneyŌM Difference: Safe, Supported, Sustainable
At JourneyŌM, we know that fast breakthroughs are just the beginning. Our mission is to ensure every seeker feels seen, supported, and safely guided—whether they’re exploring a psychedelic spray, a classic psychedelic session, or microdosing.
Our Safety Principles, Integration Resources, and carefully vetted Guides help you move from momentary relief to deep, sustainable transformation.
Ready to Learn More?
If you’re curious about how a psychedelic spray might fit into your healing journey—safely and responsibly—JourneyŌM is here to help. Take your next step today: